DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Women's Health Homepage

IBM Watson Health unveils breast advisors solution at RSNA Uses imaging analytics

RSNA highlights in digital radiography, fluoroscopy, and mammography Vendors tout advanced applications, AI, security and greater efficiencies

Community practices not abiding by breast cancer screening guidelines for MR High breast density isn't enough

Volpara brings quality control and better risk assessment to breast imaging Launches two new products as part of VolparaEnterprise platform at RSNA

Study finds Transpara deep learning CAD system performs as well as radiologists ScreenPoint solution provides cancer suspicion score from 0 to 100

Siemens unveils its MAMMOMAT Revelation mammography system at RSNA Provides automated breast density measurements at exam

Survey finds most patients prefer annual mammograms Challenges the USPSTF's recommendations

FDA greenlights GE’s SenoBright HD clinical application for breast cancer diagnosis Used to clarify inconclusive screenings

New bill calls for dense breast tissue notification in patient-received mammo reports Would set a minimum federal standard

Konica Minolta signs group purchasing agreement with Premier for the Exa platform The three-year deal brings special pricing to 3,900 hospitals

The TMIST study will determine if 3-D
mammograms reduce a woman's risk of
developing life-threatening cancer
than 2-D mammograms

Researchers to assess benefits of 3-D mammo versus 2-D

by John Fischer , Staff Reporter
A new study could determine if 3-D mammography reduces a woman’s risk of developing life-threatening breast cancer more than 2-D.

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI) have developed the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) to compare the two types of digital mammography in breast cancer screenings. ECOG-ACRIN will lead the study.

Story Continues Below Advertisement

qualiTEE - reliabiliTEE - repairabiliTEE - we guaranTEE

Bayer HealthCare Multi Vendor Service will repair your transducer with the same precision and care you provide to your patients. Now offering TotalREPAIR on 140 transducer models! Call us at 1-844-5100 or visit www.mvs.bayer.com to set up an order today.



“The information related to detecting life-threatening cancers is important because it gets to the purpose and essence of cancer screening,” Dr. Worta McCaskill-Stevens, M.D., M.S., chief of the Community Oncology and Prevention Trials Research Group at NCI, told HCB News. ”Another important aspect is that TMIST will compare the benefits and harms between 2-D and 3-D.”

3-D mammography is likely to detect more findings that require follow-ups and lead to more procedures and treatments than 2-D. It is unknown whether 3-D is better able to reduce a woman’s risk of developing an advanced, life-threatening form of cancer.

The trial will follow 165,000 women between 45 and 74 who are planning to undergo routine mammograms. Researchers will use the findings to determine the best course of action for screening women, as well as how to help women make informed decisions regarding screenings.

Participants will each be assigned to undergo either 3-D or 2-D mammogram screenings. Most will be screened annually. Postmenopausal women who show no high risk factors will be screened every two years. The study will also take into account diversity, basing participants on geographic location sites, race and ethnicity.

Data from each mammogram will be collected and evaluated, including imaging that shows no signs, suspicion or diagnosis of breast cancer. Follow-ups for imaging and biopsies will be reported. All participants will be checked for breast cancer status, treatment and outcomes from the time each starts the trial through at least 2025. Women who are diagnosed with breast cancer during any part of the study will continue to be a part of it and receive treatment.

All participants are encouraged to voluntarily submit blood samples and a swab of buccal cells from inside the mouth as part of TMIST’s effort to create a biorepository for future genetic markers for breast cancer. This will enable doctors and women to determine the best methods for screenings and evaluate risk factors of individual patients for developing diseases.

Tissue will also be collected from women who undergo biopsies as part of follow-ups for mammogram findings, allowing TMIST researchers to study the biology of screen-detected abnormalities and to evaluate the overdiagnosis of breast cancer from screenings.
  Pages: 1 - 2 >>

Women's Health Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED